Lupus skin drug shows promise in small trial
NCT ID NCT03288324
First seen Mar 05, 2026 · Last updated May 05, 2026 · Updated 13 times
Summary
This study looked at whether tofacitinib, a drug that calms the immune system, is safe and helpful for young adults (ages 18-45) with moderate to severe lupus skin disease. Thirteen people took part over 76 weeks. The goal was to see if the drug reduces skin symptoms and how the body processes it. Since lupus is a long-term condition requiring ongoing care, this treatment aims to control the disease rather than cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
MetroHealth Medical Center
Cleveland, Ohio, 44109, United States
Conditions
Explore the condition pages connected to this study.